Patent · US Active

Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

US9631004B2 · kind B2 · utility

11Cited by

172References

17Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Paul E. Morin · Pennington, US
Daniel Cohen · Watertown, US
Ranjan Mukherjee · East Lansing, US
Timothy P. Reilly · New Hope, US
Rose C. Christian · Lawrenceville, US
Dasa Lipovsek · Pepperell, US
Ray Camphausen · Wayland, US
John Krupinski · Flemington, US

Key dates

Filing date	Jul 20, 2016
Grant date	Apr 25, 2017
Priority date	—
Expiry date	Jul 20, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.